Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2016 Apr 8;30(8):1763–1766. doi: 10.1038/leu.2016.41

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Prognostic significance of IRR in patients treated with anti-CD20 monoclonal antibodies. (a) Landmark analysis (starting day 3) of rituximab-treated patients. HR=0.6, 95% CI 0.4–0.8, P=0.002; (b) Landmark analysis (starting day 3) of obinutuzumab-treated patients. HR=1.5, 95% CI 1.0–2.4, P=0.07; (c) Landmark analysis of patients treated with 6 cycles of rituximab. HR=0.7, 95% CI 0.5–0.9, P=0.01; (d) Landmark analysis of patients treated with 6 cycles of obinutuzumab. HR=1.5, 95% CI 0.9–2.6, P=0.1.